Olopatadine shortage — NZ supply status & alternatives

Olopatadine

—

🇦🇺 AUST R 82000 · Novartis Pharmaceuticals Australia Pty Ltd

In supply · Australia

Eye drops 0.1%

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇳🇿 NZ🌐 TH

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Olopatadine
Brand names	Eye drops 0.1%

Controlled substance	No

Marketing-authorisation holders	Novartis Pharmaceuticals Australia Pty Ltd, Mylan Health Pty Ltd, SEQIRUS PTY LTD, WALGREEN CO. +3 more

Registrations on file	11

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇬🇧 GB

£2.91

Drug Tariff

🇺🇸 US

US$0.90

Acquisition

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

10 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Curia Spain SauPcasIndoco Remedies LTDUsv Private LTDMsn Laboratories Private LTDFis Fabbrica Italiana Sintetici SPA+4 more

Manufacturing countries: Spain, France, India, Japan · Source: FDA List of Drug Master Files

Verified timeline regulator events

🇳🇿 21 May 2026

high reported

🇨🇦 7 Aug 2025

medium reported

🇨🇦 26 Mar 2024

medium reported

🌐 28 Dec 2022

Shortage resolved

🌐 28 Nov 2022

high reported

🌐 2 Nov 2022

Shortage resolved

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders11 registrations · 7 MA holders

Product	Strength	Form	Market	MA holder	Status
PATANOL 0.1% olopatadine hydrochloride	0.1%	—	🇦🇺 AU	Novartis Pharmaceuticals Australia Pty Ltd	Active
PALADOPT olopatadine	1 mg	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
Apotex	1 mg	—	🇦🇺 AU	—	Active
Genrx	1 mg	—	🇦🇺 AU	—	Active
RYALTRIS olopatadine	600 microgram	—	🇦🇺 AU	SEQIRUS PTY LTD	Active
Olopatadine Hydrochloride	1mg/mL	solution	🇺🇸 US	WALGREEN CO.	Active
Olopatadine Hydrochloride Ophthalmic	1mg/mL	solution	🇺🇸 US	WALGREEN COMPANY	Active
Olopatadine Hydrochloride	2mg/mL	solution	🇺🇸 US	WALGREEN COMPANY	Active
Olopatadine Hydrochloride Ophthalmic	2mg/mL	solution	🇺🇸 US	WALGREENS COMPANY	Active
Rugby Olopatadine Hydrochloride Ophthalmic	1mg/mL	solution	🇺🇸 US	RUGBY LABORATORIES	Active
Olopatadine HCl	7mg/mL	solution	🇺🇸 US	RUGBY LABORATORIES	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.